IGF2 and cancer: Loss of imprinting of IGF2, resulting in abnormal expression of IGF‐II, occurs in a number of cancers, sporadic Wilms’ tumour and often in patients with Beckwith–Wiedemann syndrome, characterized in the neonate by overgrowth with risk of developing Wilms’ kidney tumours.31 Moreover, IGF‐II is involved in cardiovascular disease, likely because it has been shown to influence the size of atherosclerotic lesions.33